Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTH.L Regulatory News (CTH)

  • There is currently no data for CTH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

16 Jun 2022 07:00

RNS Number : 0586P
CareTech Holdings PLC
16 June 2022
 

For immediate release 16 June 2022

 

CareTech Holdings PLC

("CareTech" or the "the Group")

 

Interim Results for the six months ended 31 March 2022

 

 

CareTech Holdings PLC (AIM: CTH), a pioneering provider of specialist social care and education services for adults and children in the UK, is pleased to announce its interim results for the six months ended 31 March 2022.

 

 

Financial results

 

· Group performance for H1 broadly in-line with Board expectations despite increased costs due to COVID-19 and a lower than targeted occupancy due to sector wide staffing challenges

· Revenue growth of 2.6% to £249.2m (2021: £243.0m), underlying EBITDA flat at £49.1m (2021: £49.4m) and underlying EPS growth of 1.8% to 22.73p (2021: 22.33p)

· Strong balance sheet with net debt following acquisitions at £278.3m (£258.7m at 30 September 2021) and leverage 2.8x net debt / adjusted EBITDA

· Net cash before non-underlying operating activities of £49.9m (2021: £49.2m) and operating cash flow conversion of 101.6%

· No interim dividend declared given the Company remains in an offer period pursuant to the Takeover Code

 

Operational highlights

 

· Acquisition of Rehavista GmBH, providing a significant opportunity for Smartbox to expand market share in Germany and further strengthen the Group's Technology Division

· Expansion of the Care Pathway in the United Arab Emirates ("UAE") through the acquisitions of Dmetco-Bayti and Wellness Center; and creation of the Group's International Division

· New purpose-led ESG strategy "CARE4" published outlining the Group's commitment to sustainability

 

H1 2022

H1 2021

% change

Group revenue

£249.2m

£243.0m

+2.6%

Underlying EBITDA(i)

£49.1m

£49.4m

(0.6)%

Underlying profit before tax(ii)

£32.2m

£33.6m

(4.1)%

Underlying basic earnings per share(ii)

22.73p

22.33p

+1.8%

Statutory profit before tax

£19.2m

£42.3m

(54.6)%

Statutory earnings per share

11.71p

33.37p

(64.9)%

Operating cash flow before non-underlying items

£49.9m

£49.2m

1.4%

Net debt (iii)

£278.3m

£263.1m

(5.8)%

Net assets

£405.4

£393.7m

+3.0%

Interim dividend(iv)

)))

-

4.6p

n/a

 

 

i. Underlying EBITDA is operating profit stated before depreciation, share based payments charge and non underlying items (explained in note 3 and appendix a).

ii. Underlying profit before tax and underlying basic earnings per share are stated before non underlying items (explained in note 3, appendix a and appendix b).

iii. Net debt comprises Cash and cash equivalents net of bank loans and borrowings and HP leases previously accounted for under IAS17 excluding Project Teak sale and leaseback (explained in appendix c).

iv. No interim dividend declared given the Company remains in an offer period pursuant to the Takeover Code

 

 

 

Commenting on the results, Farouq Sheikh, Executive Chairman of CareTech, said:

 

"The Group delivered a strong performance in H1 and has been broadly in-line with the Board's expectations. The Group has continued to navigate well through the various challenges presented by COVID-19, sector staff shortages and inflationary pressures.

"The Group completed a number of acquisitions during the first half of the year. The acquisition of Rehavista GmBH has added one of Germany's leading augmentative and alternative communication technology resellers to the Group, and further accelerated our growing technology offer to international markets.

"We were also pleased to complete the acquisitions of Dmetco-Bayti and the Wellness Center, building on our existing portfolio of companies in the UAE through the AS Group. These well-known local brands bolster our capability to service the UAE homecare and outpatient clinic markets and form part of our strategy to develop a "whole person" care pathway of services for people with disabilities and complex needs.

 "The Group has seen significant growth in the Digital Technology and International division and is also well positioned to continue to meet a critical social care need in the UK. CareTech remains in a strong financial position, underpinned by a significant property portfolio and consistent strong cash generation, and I remain confident in our outlook."

 

For further information, please contact:

 

CareTech Holdings PLC 01707 601800

Farouq Sheikh, Executive Chairman

Christopher Dickinson, Group Chief Finance Officer

 

Consilium Strategic Communications 020 3709 5700

Mary-Jane Elliott

Chris Welsh

Angela Gray

 

Panmure Gordon (Nomad and Joint Broker) 020 7886 2500

Emma Earl

Freddy Crossley

Charles Leigh-Pemberton

 

Numis (Joint Broker) 020 7260 1000

Jonathan Wilcox

James Black

Duncan Monteith

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

 

About CareTech

 

CareTech Holdings PLC is a leading provider of specialist social care services supporting around 5,000 adults and children with a wide range of complex needs in more than 550 services across the UK employing more than 11,000 staff; and an emerging presence in international markets

Committed to the highest standards of care and care governance, CareTech's innovative Care Pathway covers Foster Care, Children's Services, Adults Services, International and Technology Solutions. 

CareTech, which was founded in 1993, began trading on the AIM market of the London Stock Exchange in October 2005 under the ticker symbol CTH. 

For further information please visit: www.caretech-uk.com

 

Chairman's Statement

 

CareTech delivered robust operational and financial performance for the six months to 31 March 2022 that was broadly in-line with the Board's expectations. The emergence of the highly transmissible Omicron variant in early December 2021 led to sector challenges around staff absenteeism with consequential lower than targeted occupancy and higher agency costs.

Whilst the COVID-19 pandemic restrictions have been eased, we continue to have a relentless focus on the safety of our service users and maintaining a COVID-19 secure environment.

 

Possible Offers for the Company

 

As detailed in the Company's "Further Extension to Deadline Sheikh Holdings" and "Further Extension to Deadline DBAY" announcements on 30 May 2022, discussions between both the Company and a consortium consisting of Sheikh Holdings Group (Investments) Limited; together with Belgravia Investments Limited, Kensington Capital Limited and funds managed by THCS IV GP S.a.r.l and advised by THCP Advisory Limited (together, the "Consortium") and separately between the Company and DBAY Advisers Limited ("DBAY") remain ongoing. In accordance with Rule 2.6(c) of the Takeover Code, the Independent Directors of the Company have previously requested, and the Panel has previously consented to, an extension to the deadline by which both the Consortium and DBAY are required either to announce a firm intention to make an offer for CareTech in accordance with Rule 2.7 of the Takeover Code, or to announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Takeover Code applies. Such announcements must be made by not later than 5.00 p.m. on 27 June 2022. This deadline can be further extended by the Independent Directors with the consent of the Takeover Panel.

 

 

Acquisitions

 

REHAVISTA GmbH

 

On 29 November 2021 and following the acquisition of Smartbox in 2020, the Group announced the acquisition of REHAVISTA, Germany's largest provider of augmentative and alternative communication (AAC) products and services. REHAVISTA's reach and expertise is unparalleled in Germany, estimated to be the second largest funded AAC market globally after the USA. With its deep knowledge of assistive technology and established routes to market, this acquisition provides a significant opportunity for Smartbox to expand the products and services available in Germany, expanding on the existing partnership between Smartbox and REHAVISTA, and across Smartbox's global customer base, which spans more than 30 languages and 45 distributors.

 

Dmetco-Bayti / The Wellness Center

 

Following the acquisition of the American Centre for Psychiatry and Neurology and Maudsley Health (together the 'AS Group') in February 2020, the Group completed the acquisition of Wellness Center and Dmetco-Bayti has extended the care pathway to encompass specialist health and social care services in home care environments, and physical healthcare services in specialist clinic settings. CareTech's long term goal in the Gulf region is to create a world class integrated pathway of care and technology services for mental health, social care, special education, and physical healthcare, offering the widest possible access to people with complex needs and disabilities in their local communities.

Dmetco-Bayti is a well-established home healthcare provider managing the daily health and social care needs of its patients across the UAE through two home-grown brands, namely Dmetco Home Healthcare and Bayti Home Healthcare. Dmetco-Bayti provides home healthcare, physiotherapy services and rehabilitation services in the emirate of Abu Dhabi, primarily to UAE nationals, through a team of over 150 registered healthcare professionals.

The Wellness Center provides integrated physical health consultations and surgical services serving c.7000 patients per month. Wellness's operations will play an integral part of the Group's vision to provide a continuum of care for AS Group's mental healthcare patients through quality day care, GP and other specialist services.

Both Dmetco-Bayti and Wellness are managed through our existing AS Group led by Shafqat Malik as CEO.

 

 

Financial Results

 

Group revenues increased by 2.6% to £249.2m (March 2021: £243.0m) with increases in the Adults, International and Digital divisions offset by a decline in targeted occupancy in the Children's and Fostering division largely due to sector wide staffing challenges.

From 1 April 2022, the Group increased the minimum national hourly rate to £9.75 which is above the National Living Wage hourly rate of £9.50. In the trading update issued on 3 May 2022, the Group announced that annual fee rate negotiations with local authorities have begun and the Group anticipate a favourable response despite the National Living Wage increase and other inflationary pressures. Despite inflationary pressures, Local Authorities recognise that front line staff are an integral part of the quality of care delivery and the Group expects fee increases to cover the majority of additional costs.

Divisional EBITDA before unallocated costs remained broadly flat at £61.8m (2021: £62.0m) and Group underlying EBITDA(i) was £49.1m (2021: £49.4m). Underlying EBITDA(i) margin decreased slightly to 19.7% from 20.3%.

Finance costs increased to £7.1m (2021: £6.3m) reflecting incremental debt used to finance acquisitions.

Underlying profit before tax(ii) marginally decreased to £32.2m (2021: £33.6m) and underlying basic earnings per share(ii) increased to 22.73p (2021: 22.33p). The Group's underlying tax charge was £7.0m, which represents an effective tax rate of 14.1% which is lower than the headline rate of corporation tax of 19% due to the super deduction for capital allowances (130% deduction for qualifying expenditure). 

Underlying EBITDA to cash conversion(iii) was £49.9m which represents a cash conversion rate of 101.6% for the period from 1 October 2021 to 31 March 2022. Key cash flow items during the first half include £8.1m on the acquisition of REHAVISTA, £9.7m on the acquisitions of Dmetco-Byati and The Wellness Group, £7.1m development capex, £6.7m on maintenance capex, £2.4m software development capex, payment of the interim dividend of £5.2m for the six months ended 31 March 2022, interest of £6.6m and corporation tax of £8.7m.

Non underlying items includes £5.1m of costs as a consequence of COVID-19 which have in part been funded by £1.6m of Government Social Care support through the Infection Control and Testing Fund and Workforce Recruitment and Retention Fund. Other non-underlying costs consist of £0.7m contribution to the CareTech Charitable Foundation and £3.0m acquisition and integration costs.

Statutory profit before tax decreased to £19.2m (2021: £42.3m) and statutory basic earnings per share decreased to 11.71p (2021: 33.37p), primarily due to the write back of £11.8m sleep-in provision in March 21 and the gain on bargain purchase arising from the Huntercombe acquisition in the prior period.

Net assets have increased to £405.4m as at 31 March 2022 (2021: £393.7m).

 

Operating review

The overall performance of the Group is broadly in-line with the Board's expectations, with the effects of labour shortages and the emergence of the highly transmissible Omicron variant in early December 2021 leading to challenges around staff absentees with consequential lower targeted occupancy and higher agency costs. Accordingly, COVID-19 costs have occurred during the first half which have in part been funded by Government Social Care support through the Infection Control and Testing Fund and Workforce Recruitment and Retention Fund. Whilst COVID-19 self-isolation restrictions have now been lifted in the UK and costs reduced, the Group continues to ensure our services are safe for both our staff and services users and maintaining a COVID-secure environment. 

The Group's net capacity as at 31 March 2022 was 4,902 places (September 21: 4,979 places) and occupancy levels in the mature estate increased to 84% (September 2021: 80%) with blended occupancy increasing to 81% (September 2021: 78%).

Following the acquisition of Dmetco-Byati and the Wellness Center and the growth of our operations in the Gulf, the Group has created a new International reporting segment. A review of each operational division is set out below:

 

(1) Adults Services

 

 

 

Half Year

 

2022

2021

% change

Revenue

£79.4m

£76.6m

3.7%

EBITDA before unallocated costs

£18.2m

£18.0m

1.6%

EBITDA margin

23.0%

23.5%

 

 

Adults Services capacity decreased to 2,083 (September 2021: 2,104) which was attributable to the closure of 23 beds, 31 contract wins and 29 withdrawals. Revenue increased by 3.7% to £79.4m and EBITDA increased to £18.2m.

Demand for services remains high with a strong pipeline of referrals in both community based living and high acuity mental health services. The division continues to fill available capacity and is working at retooling services to meet commissioner demand. Occupancy has been impacted by recognised staffing challenges across the sector, clear steps have been taking to address this in H1 with a strong overseas recruitment focus.

 

CQC ratings as at 31 March 2022 were 84% Good or Outstanding (September 2021: 86%) across the division with quality improvement plans in place to address those services that are rated "Requires Improvement" or "Inadequate".

 

(2) Children's Services

 

 

 

 

Half Year

 

2022

2021

% change

Revenue

£121.6m

£127.9m

(4.9)%

EBITDA before unallocated costs

£35.5m

£37.2m

(4.6)%

EBITDA margin

29.2%

29.1%

 

 

Capacity marginally decreased to 1,996 (September 2021: 2,000) with the addition of 14 beds opening offset by 18 bed closures/ occupancy changes. Revenue and EBITDA decreased by 4.9% and 4.6% respectively.

 

Demand for services remains high with a strong pipeline of referrals. The Group has implemented positive fee increases but financial performance has been impacted by a lower targeted occupancy due to recognised staffing challenges

OFSTED ratings remain high at 77% "Good" or "Outstanding" as at 31 March 2022 (September 2021: 80%). The Group remains committed to providing the highest quality standard of care to those it looks after and we have a clear focus on early intervention and quality improvement plans in all services, with a stronger and dedicated focus to address those services that are not "Good" or "Outstanding".

 

(3) Foster Care

 

 

 

Half Year

 

2022

2021

% change

Revenue

£17.6m

£19.3m

(8.4)%

EBITDA before unallocated costs

£3.2m

£3.9m

(15.7)%

EBITDA margin

18.4%

20.0%

 

 

Revenue and underlying EBITDA decreased to £17.6m and £3.2m respectively. Capacity decreased by 52 places due to foster parent leavers and in some cases young people remaining in placement post-independence.

 

Fostering operationally performed solidly, this was despite a number of foster carer moving in the period and against a challenging backdrop of new carer recruitment due to the pandemic. The focus continues to be to maintain our presence in terms of placements and fees in a highly competitive segment.

OFSTED ratings for all our Foster Care services are 100% "Good" or "Outstanding" (September 2021: 100%).

 

 

(4) Digital Technology

 

Following the acquisition of Smartbox in October 2020, the Group announced that it had acquired Rehavista in November 2021 which provides a significant opportunity for Smartbox to expand the availability of their products in Germany. This continues CareTech's ambition to develop a sector first Digital Pathway of services.

 

Half Year

 

2022

2021

% change

Revenue

£12.9m

£6.4m

99.7%

EBITDA before unallocated costs

£2.0m

£1.1m

77.5%

EBITDA margin

15.5%

17.5%

 

 

 

The division delivered strong performance in H1, ending the period with revenues at £12.9m, 99.7% up on the previous year. On a like-for-like basis, revenue was up 23% with a total of 1,348 devices sold in 21 countries around the world. 

The US market continues to be a strategic priority for Smartbox and further investment has been made to build sales and service teams of 14 people, resulting in sales of £1.3m in H1, a 120% increase from the same period last year.

 

Following the acquisition of REHAVISTA, the integration project has focussed on further developing the localisation of Smartbox products in German. In combination with intensive training for REHAVISTA sales representatives, the integration project has already led to almost 1000 Smartbox devices sold in Germany in H1. 

 

In the UK, the Smartbox team have continued working closely with CareTech services across the country as part of the 100 Voices project. 694 CareTech staff have now completed AAC training and their on-going support has started to make a significant impact on the communication skills of people provided with a device.

 

 

(5) International

 

 

 

Half Year

 

2022

2021

% change

Revenue

£17.7m

£12.9m

36.9%

EBITDA before unallocated costs

£2.9m

£1.9m

51.2%

EBITDA margin

16.1%

14.6%

 

 

 

As the Company's international revenues grow, the Company has established a new International division. The division delivered a strong financial performance in the first half, despite challenging conditions due to COVID-19. Revenues increased by 36.9% and EBITDA by 51.2% with the division increasing the clinicians to satisfy the increased demand in mental health services. The outpatients' clinics in Abu Dhabi and Dubai relocated during the first half which will create an additional 25% capacity for organic growth.

Following CareTech's first international investment in the UAE, the Group announced two further acquisitions as part of its strategy to develop a whole person care pathway of services for people with complex needs and disabilities. Dmetco-Bayti is a well-established home healthcare provider managing the daily health and social care needs of its patients across the UAE and the Wellness Group provides integrated physical health consultations and surgical services. Both acquisitions will expand the care pathway to encompass specialist health and social care services in home care environments, and physical healthcare services in specialist clinic settings.

Net debt

 

As at 31 March 2022, unaudited net debt was £278.3m compared with £258.7m at 30 September 2021, with net debt/unaudited adjusted EBITDA 2.8x. The Group generated operating free cash flow of £49.9m which has primarily been offset by the acquisitions of REHVISTA, Dmetco-Bayti and The Wellness Group, capital expenditure of £16.2m, shareholder dividends of £5.2m and exceptional costs of £7.9m.

 

Our People

Staff retention at 31 March increased to 72% (September 21: 71%). Whilst resourcing remains challenging across the sector, the retention rate remains positive and is higher than the industry average. Our focus remains on following through on broader attraction programmes such as overseas recruitment. To date we have hired 222 overseas qualified nurses who will join us as senior support workers. We welcomed the first cohort to our Whitson Service on 14 May 2022. The second half of the year will focus deploying our young people strategy that will aim to open the care sector up to young people with the opportunity to study and build a career in the sector.

 

To further support our recruitment drive the Group has implemented a new Applicant Tracking System ('ATS') platform which will support the traditional recruitment methods by improving the time to hire, driving candidate centric recruitment process and simplifying the on-boarding experience.

 

Our commitment to improve retention rates further is demonstrated through the launch of the new Employee Service Centre. This team will be interacting with those employees beginning their employment with CareTech. They will ensure that all staff are contacted at vital touch points. This will serve to provide welfare and support to ensure that early intervention measures are in place, so that our staff feel supported to deliver great quality care. This intervention of sign posting staff will enhance the employee's induction to CareTech with a view to strengthening the 'staff voice'.

 

Employee well-being remains a key focus. Through our well-being strategies, we continue to drive the 'let's talk' campaign, this is to ensure that our staff make time to enquire about each other's welfare. This is continuing to build the organisational desire to promote CareTech as a 'family'. Our ultimate commitment is to provide an organisation which promotes a safe space and supports employee well-being.

 

Social Responsibility

 

Underscoring our commitment as a purpose-led business, we published our first Purpose Report alongside our Annual Report in February 2022. The Purpose Report set out our ambitious CARE4 Responsible Business Strategy, a comprehensive Group-wide programme to deliver our commitment to our people, our planet, our communities and to innovation. CARE4 sets out our commitments, goals and measures for sustainability and provides a framework for us to track and report progress. The strategy is fully-aligned with our corporate strategy and is rooted in our clear and powerful social outcomes, which we will seek to embed in a new set of social impact outcome measures.

 

The CARE4 Strategy sets out clear headline commitments for each pillar of our Strategy which will be underpinned by a detailed set of targets across all areas:

 

· CARE4 People: We will be an employer of choice, investing in our people and valuing their diversity

· CARE4 Planet: We will be a Net Zero business by 2050

· CARE4 Innovation: We will have established our new CareTech Technology division to spearhead our technology and innovation agenda

· CARE4 Community: We will donate a percentage of our annual pre-tax profits to the CareTech Foundation

 

The Purpose Report also included the Group's first report against the World Economic Forum's ESG framework, demonstrating our commitment as a responsible business and responsibility to all of our stakeholders. 

 

The Group was thrilled that its commitment to charitable causes was recognised in the Better Society Awards 2022, winning the Philanthropy Award.

 

During the first half, the independent CareTech Charitable Foundation has continued to make a significant contribution to the social care sector, including:

· A major new partnership with the Royal National Institute of Blind People (RNIB to increase awareness and understanding of the impact of sight loss for people with learning disabilities;

· The launch of the CareTech Foundation Care Leavers Bursary Grant scheme in partnership with the University of East London, incorporating work experience opportunities with financial support to inspire other care and educational institutions to provide the necessary support for care-experienced students; and

· Support for an exciting new programme with Carers Worldwide to support unpaid carers in Bangladesh.

 

The success of the CareTech Foundation has received significant recognition for its growing impact this period, including winning the Trustee Board of the Year at the Charity Times Awards and the Foundation has been short-listed in the Corporate Foundation of the Year category of Third Sector's Business Charity Awards.

 

Dividend

 

No interim dividend has been declared given the Company remains in an offer period (2021: 4.6p). In the event that the proposed takeover does not go ahead and the Company ceases to be in an offer period pursuant to the Takeover Code, the Board may review whether to declare a special dividend in lieu of an interim dividend.

 

Outlook and prospects

 

CareTech's aim is the provision of first-class social care and through the use of technology we will look to deliver innovative services focussed on delivering positive outcomes for individuals.

 

Underlying trends remain positive for the Group despite being set against a challenging staffing backdrop and inflationary pressures. The Group remains in a strong financial position and we are well placed to offer high quality care to our service users, which represents good value to Commissioners.

 

Farouq Sheikh

Chairman 

16 June 2022

(i) Underlying EBITDA is operating profit before depreciation, share-based payments charge and non underlying items (explained in note 3 and appendix a);

(ii) Underlying profit before tax and underlying diluted earnings per share are stated before non underlying items (explained in note 3, appendix a and appendix b).

(iii) EBITDA to cash conversion is calculated as operating cash flows before non underlying items divided by underlying EBITDA

 

 

 

 

Condensed Consolidated Statement of Comprehensive Income

for the six months ended 31 March 2022

 

 

Six months ended

Six months ended

Year ended

31 March 2022

31 March 2021

30 September 2021

unaudited

unaudited

audited

Before non

 

Before non

Before non

underlying

Total

underlying

Total

underlying

Total

items(i)

unaudited

items(i)

unaudited

items(i)

audited

Note

£000

£000

£000

£000

£000

£000

Revenue

2

249,248

249,248

242,964

242,964

489,119

489,119

Cost of sales

(165,027)

(165,027)

(160,441)

(160,441)

(323,410)

(323,410)

Gross profit

84,221

84,221

82,523

82,523

165,709

165,709

Other income

-

1,559

-

1,181

-

2,692

Administrative expenses

(45,080)

(59,423)

(42,823)

(35,028)

(85,216)

(88,897)

Operating profit

39,141

26,357

39,700

48,676

80,493

79,504

 

 

Underlying EBITDA (i)

49,086

50,645

49,359

50,540

100,485

103,177

Depreciation

(9,708)

(9,708)

(9,422)

(9,422)

(19,519)

(19,519)

Share-based payments charge

 

(237)

(237)

(237)

(237)

(473)

(473)

Non underlying items

3

-

(14,343)

-

7,795

-

(3,681)

Operating profit

 

39,141

26,357

39,700

48,676

80,493

79,504

 

 

Financial expenses

4

(6,905)

(7,130)

(6,097)

(6,329)

(12,158)

(13,270)

Profit before tax

 

32,236

19,227

33,603

42,347

68,335

66,234

Taxation

5

(4,530)

(3,734)

(7,029)

(3,541)

(11,889)

(30,906)

Profit for the period

27,706

15,493

26,574

38,806

56,446

35,328

Non-controlling interest

(2,511)

(2,511)

(1,852)

(1,852)

(3,420)

(3,420)

 

Profit for the period attributable to equity shareholders of the parent

 

 

 

 

 

25,195

 

 

 

12,982

 

 

 

24,722

 

 

 

36,954

 

 

 

53,026

 

 

31,908

Earnings per share

 

 

 

Basic

6

 

11.71p

33.37p

28.80p

Diluted

6

 

11.12p

31.79p

27.48p

 

 

 

 

 

 

Profit for the year attributable to owners of the parent:

 

 

Exchange movements on overseas net assets

969

969

(623)

(623)

(424)

(424)

 

 

Items that will not be reclassified to income statement:

 

 

Exchange movements on overseas net assets of non-controlling interest

407

407

(547)

(547)

(320)

(320)

 

 

Other comprehensive income for the year

1,376

1,376

(1,170)

(1,170)

(744)

(744)

 

 

Total comprehensive income for the year

29,082

16,869

25,404

37,636

55,702

34,584

 

 

 

Non-controlling interest

(2,918)

(2,918)

(1,305)

(1,305)

(3,100)

(3,100)

 

 

Profit for the year attributable to owners of the parent

26,164

13,951

24,099

36,331

52,602

31,484

 

 

 (i) Underlying EBITDA is operating profit before depreciation, share-based payments charge and non underlying items (explained in note 3 and appendix a).

Condensed Consolidated Statement of Changes in Equity at 31 March 2022

 

 

Share

capital

Share

premium

Shares held by Executive Shared Ownership Plan

Merger

reserve

Foreign Currency Translation Reserve

Retained

earnings

Total Attributable to owners of the parent

Non-controlling Interest

Total

Equity

 

£000

£000

£000

£000

£000

£000

£000

£000

£000

 

At 1 October 2020

565

133,079

(13,305)

125,842

53

107,120

353,354

10,862

364,216

Profit for the year

-

-

-

-

-

31,908

31,908

3,420

35,328

Other comprehensive income

-

-

-

-

(424)

-

(424)

(320)

(744)

 

 

 

 

 

 

 

 

 

 

Issue of ordinary shares

1

472

-

-

-

-

473

-

473

Redemption of share options

-

-

468

-

-

-

468

-

468

Equity-settled share-based payments charge

-

-

-

-

-

1,373

1,373

-

1,373

Acquisition

-

-

-

-

-

-

-

1,450

1,450

Recognition of liabilities with non-controlling interest

-

-

-

-

-

(4,351)

(4,351)

-

(4,351)

Dividends

-

-

-

-

-

(14,431)

(14,431)

(2,865)

(17,296)

Transactions with owners recorded directly in equity

1

472

468

-

(424)

14,499

15,016

1,685

16,701

At 30 September 2021

566

133,551

(12,837)

125,842

(371)

121,619

368,370

12,547

380,917

Profit for the year

-

-

-

-

-

12,982

12,982

2,511

15,493

Other comprehensive income

-

-

-

-

969

-

969

407

1,376

Issue of ordinary shares

-

-

-

-

-

-

-

-

-

Redemption of share options

-

56

19

-

-

-

75

-

75

Equity-settled share-based payments charge

-

-

-

-

-

969

969

-

969

Acquisition (Note 7)

-

-

-

-

-

-

-

8,268

8,268

Dividends

-

-

-

-

-

(5,209)

(5,209)

-

(5,209)

Other movement in non-controlling interest

-

-

-

-

-

-

-

3,540

3,540

Transactions with owners recorded directly in equity

-

56

19

-

969

8,742

9,786

14,726

24,512

At 31 March 2022

566

133,607

(12,818)

125,842

598

130,361

378,156

27,273

405,429

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Condensed Consolidated Balance Sheet at 31 March 2022

 

31 March 2022

31 March

2021

30 September

2021

unaudited

unaudited

audited

£000

£000

£000

Non-current assets

 

 

Property, plant and equipment

630,019

617,498

619,482

Right-of-use-assets

124,820

113,160

123,231

Other intangible assets

101,755

90,296

87,032

Goodwill

105,330

86,716

86,866

961,924

907,670

916,611

Current assets

 

Inventories

5,692

3,003

3,468

Trade and other receivables

83,512

64,627

71,606

Cash and cash equivalents

47,226

61,290

65,560

136,430

128,920

140,634

Total assets

1,098,354

1,036,590

1,057,245

 

Current liabilities

 

Trade and other payables

76,973

65,057

70,011

Contingent consideration payable

7,368

4,537

3,616

Lease liabilities

5,876

5,098

5,500

Deferred income

43,081

35,258

36,132

Corporation tax

10,749

14,053

17,753

144,047

124,003

133,012

Non-current liabilities

 

Loans and borrowings

321,036

319,481

319,654

Contingent consideration payable

1,100

-

-

Provisions

5,190

7,545

5,540

Lease liabilities

120,303

115,040

118,781

Deferred tax liabilities

96,307

70,876

93,927

Derivative financial instruments

4,942

5,942

5,414

548,878

518,884

543,316

Total liabilities

692,925

642,887

676,328

Net assets

405,429

393,703

380,917

 

Equity attributable to equity shareholders of the parent

Share capital

566

565

566

Share premium

133,607

133,446

133,551

Shares held by Employee Benefit Trust

(12,818)

(12,916)

(12,837)

Merger reserve

125,842

125,842

125,842

Other reserves

-

(570)

-

Foreign currency translation

598

-

(371)

Non-controlling interest

27,273

11,571

12,547

Retained earnings

130,361

135,765

121,619

Total equity attributable to equity shareholders of the parent

405,429

393,703

380,917

 

Consolidated Cash Flow Statement for the six months ended 31 March 2022

 

Six months ended

Six months ended

Year ended

31 March 2022

31 March 2021

30 September 2021

unaudited

unaudited

audited

£000

£000

£000

Cash flows from operating activities

 

 

Profit before tax

19,227

42,347

66,234

Financial expenses

7,130

6,329

13,270

Depreciation

9,708

9,422

19,519

Amortisation of intangible assets

5,574

5,184

10,273

Impairment of goodwill

-

584

-

Sleep-in provision

-

(11,777)

(11,777)

Gain on bargain purchase

-

(5,758)

(5,758)

Share-based payments charge

960

567

1,373

Other non-cash items

-

-

587

Operating cash flows before movement in working

42,599

46,898

93,721

capital

 

Increase in inventory

(606)

(197)

(651)

Decrease/(increase) in trade and other receivables

183

(8,285)

(15,953)

Increase in trade and other payables

1,247

8,008

12,715

Cash inflows from operating activities

43,423

46,424

89,832

Tax paid

(8,687)

(5,423)

(6,038)

Net cash from operating activities

34,736

41,001

83,794

 

Cash flows from investing activities

 

 

Proceeds from sale of property, plant and equipment

528

-

1,299

Business combinations net of cash acquired (Note 7)

(17,825)

(5,447)

(5,447)

Acquisition of property, plant and equipment

(16,185)

(13,432)

(28,993)

Acquisition of software

(1,485)

(1,286)

(2,938)

Payment of deferred consideration

(3,050)

-

(1,503)

Net cash used in investing activities

(38,017)

(20,165)

(37,582)

Cash flows from financing activities

 

Proceeds arising from the issue of share capital (net of costs)

75

756

941

Interest paid

(6,636)

(3,941)

(10,599)

Cash outflow arising from non underlying finance expenses

(697)

(645)

(1,756)

Loan arrangement fee

-

-

(438)

Payment of finance lease liabilities

(2,586)

(4,457)

(5,777)

Dividends paid to non-controlling interest

-

(1,007)

(2,865)

Dividends paid

(5,209)

(4,525)

(14,431)

Net cash utilised in financing activities

(15,053)

(13,819)

(34,925)

Net change in cash and cash equivalents

(18,334)

7,017

11,287

Cash and cash equivalents at start of the period

65,560

54,273

54,273

Cash and cash equivalents at end of the period

47,226

61,290

65,560

 

 

 

Notes

 

1. Accounting policies

 

This interim report has been prepared on the basis of the accounting policies expected to be adopted for the year ending 30 September 2022. These are anticipated to be in accordance with the Group's accounting policies as set out in the latest annual financial statements for the year ended 30 September 2021.

The Group financial statements have been prepared in accordance with International Financial Reporting Standards as adopted by UK-IFRS and those parts of the Companies Act 2006 as required to be adopted by AIM-listed companies. AIM-listed companies are not required to comply with IAS 34 'Interim Financial Reporting' and accordingly the Company has taken advantage of this exemption.

In the current year, the following new and revised standards and interpretations have been adopted:

 

Title

Subject

Amendment to IFRS 16 'Leases' COVID-19 - Related Rent

Concessions beyond 30 June 2021

COVID-19 - Related Rent Concessions

Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16

Interest Rate Benchmark Reform - Phase 2

 

The amendments and interpretations listed above which were adopted did not affect the amounts reported in these interim financial statements.

 

The financial information in this interim report does not constitute statutory accounts for the six months ended 31 March 2022 and should be read in conjunction with the Group's annual financial statements for the year ended 30 September 2021. Financial information for the year ended 30 September 2021 has been derived from the consolidated audited accounts for that period which were unqualified.

 

The condensed consolidated interim financial statements for the six months to 31 March 2022 have not been audited or reviewed by auditors pursuant to the Auditing Practices Board guidance on Review of Interim Financial Information.

This unaudited interim report was approved by the Board on 15 June 2022.

Going concern

 

The Group is financed by bank loan facilities that mature in August 2023. The Directors have considered the Group's forecasts and projections, and the risks associated with their delivery, and are satisfied that the Group will be able to operate within the covenants imposed by bank loan facilities for at least twelve months from the date of approval of the condensed consolidated financial information. In relation to available cash resources, the Directors have had regard to both cash at bank and a £25m committed undrawn revolving credit facility. The Directors have therefore concluded it is appropriate to prepare the accounts on a going concern basis.

 

2. Segmental information

 

IFRS 8 requires operating segments to be determined based on the Group's internal reporting to the Chief Operating Decision Maker ("CODM"). The CODM has been determined to be the Chief Executive Officer as he is primarily responsible for the allocation of resources to segments and the assessment of the performance of each of the segments.

The CODM uses underlying EBITDA as reviewed at monthly Executive Committee meetings as the key measure of the segments' results as it reflects the segments' underlying trading performance for the period under evaluation. Underlying EBITDA is a consistent measure within the Group. During the year, following the acquisitions of Dmetco-Bayti and the Wellness Group, the Company's international revenues have grown. As a result the reportable segment structure used in the prior year is no longer a reflection of how the CODM assesses the performance of segments and allocates resources to segments. A new International segment has now been reported on.

Inter-segment turnover between the operating segments is not material.

The interim results report segmental information on the Group's five reporting segments (and the comparative information has been represented on this basis):

· Adults Services;

· Children's Services;

· Foster Care;

· Digital Technology; and

· International

 

The condensed segmental results for the six months ended 31 March 2022, six months ended 31 March 2021 and year ended 30 September 2021 and the reconciliation of the segment measures to the respective statutory items included in the consolidated financial information are as follows:

 

 

Six months ended

Six months ended

Year ended

31 March 2022

31 March 2021

30 September 2021

unaudited

unaudited

unaudited

£000

£000

£000

Adults Services

 

Client capacity

2,083

2,140

2,104

Revenue

79,405

76,559

157,137

EBITDA before unallocated costs

18,248

17,970

36,692

 

Children's Services

 

Client capacity

1,996

1,981

2,000

Revenue

121,627

127,885

256,032

EBITDA before unallocated costs

35,474

37,187

74,497

 

Foster Care

 

Client capacity

823

1,014

875

Revenue

17,643

19,252

38,160

EBITDA before unallocated costs

3,244

3,847

7,718

 

Digital Technology

 

Revenue

12,881

6,449

12,932

EBITDA before unallocated costs

1,999

1,126

2,427

 

International

 

Revenue

17,693

12,920

25,054

EBITDA before unallocated costs

2,852

1,886

3,336

 

Total

 

Client capacity

4,902

5,135

4,979

Revenue

249,249

243,065

489,315

EBITDA before unallocated costs

61,817

62,016

124,670

Total Group revenue

Segmental revenue

249,249

243,065

489,315

Less: Intercompany sales and other revenue

(1)

(101)

(196)

Group revenue

249,248

242,964

489,119

 

Reconciliation of EBITDA to profit after tax

 

Six months ended

Six months ended

Year ended

 

31 March 2022

31 March 2021

30 September 2021

 

unaudited

unaudited

audited

 

£000

£000

£000

Underlying EBITDA before unallocated costs

61,817

62,016

124,670

Unallocated corporate overheads

(12,731)

(12,657)

(24,185)

Underlying EBITDA

49,086

49,359

100,485

Depreciation

(9,708)

(9,422)

(19,519)

Share-based payments charge

(237)

(237)

(473)

Non underlying items

(12,784)

8,976

(989)

Operating profit

26,357

48,676

79,504

Financial expenses

(7,130)

(6,329)

(13,270)

Profit before tax

19,227

42,347

66,234

Taxation

(3,734)

(3,541)

(30,906)

Profit after tax

15,493

38,806

35,328

Profit attributable to: Owners of the parent

12,982

36,954

31,908

Non-controlling interest

2,511

1,852

3,420

 

Operations of the Group are primarily carried out in the UK, the Company's country of domicile. The AS Group, registered in the United Arab Emirates ("UAE") has generated revenue in the UAE (£17.7m). On 4 February 2022 the Group acquired control of Dmetco-Bayti Group and Wellness Group, these fall part of the AS Group. Revenue by Digital Technology has been generated in Europe (£7.6m), North and Central America (£2.7m), Australasia (£0.3m) and Middle East and Africa (£0.4m). All other revenues arise within the UK. On 29 November 2021 the Group acquired control of REHAVISTA GmBH ('REHAVISTA') and its subsidiary LogBUK, these fall part of Digital Technology

No asset and liability information is presented above as this information is not allocated to operating segments in the regular reporting to the Group's CODM and are not measures used by the CODM to assess performance and to make resource allocation decisions.

 

3. Non underlying items

 

Non underlying items are those items of financial performance which, in the opinion of the Directors, should be disclosed separately in order to improve the readers understanding of the trading performance of the Group. Non underlying items comprise the following:

Six months ended

Six months ended

Year

ended

31 March 2022

31 March 2021

30 September 2021

unaudited

unaudited

audited

Note

£000

£000

£000

COVID-19 income

(i)

(1,559)

(1,181)

(2,692)

 

Included in operating profit

 

(1,559)

(1,181)

(2,692)

 

 

 

 

Amortisation of intangible assets

(ii)

5,574

5,184

10,273

COVID-19 expense

(i)

5,116

1,977

4,220

Acquisition expenses

(iii)

1,042

423

759

Sleep-in provision

(iv)

-

(11,777)

(11,777)

Gain on bargain purchase

(v)

-

(5,758)

(5,758)

Integration and restructuring costs

(vi)

1,952

971

4,761

Charitable donations

(vii)

659

601

1,203

Goodwill write off

-

584

-

 

Included in administrative expenses

14,343

(7,795)

3,681

 

 

 

Fair value movements relating to derivative financial instruments

 

(viii)

 

(635)

 

(759)

 

(1,441)

Charges relating to derivative financial instruments

viii)

464

606

1,195

Put-option interest

(ix)

163

152

310

Interest on contingent consideration

(ix)

-

-

582

Leases imputed interest

233

233

466

 

Included in financial expenses

225

232

1,112

 

 

 

Tax on non underlying items

Tax effect:

 

Current tax

(x)

(1,031)

(1,976)

(1,116)

Deferred tax 

(xi)

235

(1,512)

20,133

 

Included in taxation

(796)

(3,488)

19,017

Total non underlying (income)/expenses

12,213

(12,232)

21,118

 

(i) The Group has incurred additional costs as a result of COVID-19 in relation to higher sickness absence rates, personal protective equipment ('PPE') costs, infection control and higher administration costs. The Group has received additional funding by way of Government grants through local authorities to assist in dealing with this. The Group has worked closely with all local authorities in establishing a dedicated funding arrangement to support our services which has been collected to offset the additional costs, as noted above, that the Group has incurred in relation to COVID-19. COVID-19 is unprecedented, and along with the size it meets the Group's definition of non-underlying.

(ii) Amortisation relates primarily to acquisition-related intangible assets which are considered unique to a specific acquisition, whereas other development costs amortisation commences when system is launched. These costs, by their nature, can vary by size and amount each year. As a result, amortisation of intangibles is added back to assist with the understanding of the underlying trading performance of the business and to allow comparability.

(iii) In accordance with IFRS 3 (as revised) items associated with business combinations have been taken to the income statement as incurred. These items are considered specific one-off costs that occur for an acquisition that will not continue following completion.

(iv) The Group held a sleep-in provision of £11.8m for the 2020 financial year end. On 24 March 2021, the Supreme Court made a final judgement that social care staff are not entitled to the national minimum wage for sleep-in shifts and the provision of £11.8m has been written back. The provision was primarily as a result of the acquisition of the Cambian Group in October 2018. The Directors have determined this should be adjusted from underlying due to its size, nature and incidence.

(v) Gain on bargain purchase arises from assets transferred from The Huntercombe Group acquired in 2021. An adjustment is made as this is unlikely to recur due to its size, nature and occurrence to ensure comparability.

(vi) Integration costs incurred on the acquisition of REHAVISTA, Dmetco-Byati and Wellness in November 2021 and February 2022 respectively.

(vii) These charges represent charitable donations made to the CareTech Foundation, an independent grant-making corporate foundation registered with the Charity Commission. Funded and founded by the Group, the Foundation has a number of independent Trustees responsible for delivering its Charitable Objects. The Trustees also include Haroon and Farouq Sheikh OBE and Christopher Dickinson, Directors of the Group. The Group is not obliged to make these donations and this does not represent its underlying operations and consequently adjusted due to its nature.

(viii) Non-underlying items relating to the derivative financial instruments include the movements during the year in the fair value of the Group's interest rate swaps which are not designated as hedging instruments and therefore do not qualify for hedge accounting, together with the quarterly cash settlements and accrual thereof.

(ix) Contingent consideration of £3.5m was recognised following the acquisition of Smartbox during the 2021 financial year end. This was discounted back to present value and as a result a recognition of interest on contingent consideration was recognised. Additionally a put option was recognised at its present value. Interest on the put option will be recognised as a result. These are both considered costs of the acquisition and consequently adjusted for due to their nature.

(x) Represents the current tax on items (i), (iii) and (vii) above.

(xi) Deferred tax arises in respect of the following:

Six months ended

Six months ended

Year

Ended

31 March 2022

31 March 2021

30 September 2021

unaudited

unaudited

audited

£000

£000

£000

Derivative financial instruments

(121)

(144)

611

Intangible assets

569

714

1,422

Fixed assets

-

942

-

Change in tax rate

(683)

-

(22,085)

Prior year adjustments

-

-

 (81)

Total

(235)

1,512

(20,133)

 

 

4. Financial expenses

 

Six months

ended

Six months ended

Year

ended

31 March 2022

31 March 2021

30 September 2021

unaudited

unaudited

audited

£000

£000

£000

On bank loans and overdrafts

4,785

4,257

8,236

Interest expenses on lease liabilities

2,120

1,840

3,922

Financial expenses before non underlying items

6,905

6,097

12,158

Amounts relating to derivative financial instruments (note 3) 

(8)

(153)

64

Leases imputed interest (note 3)

233

233

466

Interest on contingent consideration

-

152

582

Total financial expenses

7,130

6,329

13,270

 

 

5. Taxation

 

Six months

ended

Six months ended

Year

ended

31 March 2022

31 March 2021

30 September 2021

unaudited

unaudited

audited

£000

£000

£000

Current tax expense

 

 

Current period

(2,653)

(6,738)

(10,697)

Non underlying items (note 3)

1,031

1,976

1,116

Prior year adjustments

-

-

505

Total current tax

(1,622)

(4,762)

(9,076)

 

Deferred tax expense

 

Current period

(1,877)

(291)

(1,273)

Deferred tax on non underlying items (note 3)

(235)

1,512

 (20,133)

Prior year adjustments

-

-

(424)

Total deferred tax

(2,112)

1,221

(21,830)

Total tax in the consolidated statement of comprehensive income

(3,734)

(3,541)

(30,906)

Effective tax rate on profit before tax (before non underlying items)*

14.1%

20.9%

17.4%

\* The underlying effective tax rate for the interim period was 14.1% (2021 interim: 20.9%). CareTech expects the full year underlying effective tax rate to be 12.7%.

 

On 3 March 2021, the Government announced an increase in the rate of corporation tax to 25% effective from 1 April 2023. This tax rate change has been substantively enacted in the Finance Bill 2021.

 

 

 

6. Earnings per share

Six months ended

Six months ended

Year

ended

31 March 2022

31 March 2021

30 September 2021

unaudited

unaudited

Audited

£000

£000

£000

Profit attributable to ordinary shareholders

12,982

36,954

31,908

Non underlying (income)/expenses (note 3)

12,213

(12,232)

21,118

Profit attributable to ordinary shareholders before underlying items

25,195

24,722

53,026

Weighted number of shares in issue for basic earnings per share

110,830,381

110,735,386

110,775,312

Effects of share options in issue

5,890,642

5,494,231

5,358,397

Weighted number of shares in issue for diluted earnings per share

116,721,023

116,229,617

116,133,709

 

Diluted earnings per share is the basic earnings per share adjusted for the dilutive effect of the conversion into fully paid shares of the weighted average number of share options outstanding during the period.

 

 

Earnings per share (pence per share)

 

Basic

11.71 p

33.37p

28.80p

Diluted

11.12 p

31.79p

27.48p

Earnings per share before non underlying items (pence per share)

 

Basic

22.73 p

22.33p

47.87p

Diluted

 21.59 p

21.27p

45.66p

 

 

7. Business Combinations

 

REHAVISTA

 

On the 29 November 2021, the Group acquired a 100% holding in REHAVISTA GmbH and its subsidiary LogBUK (Collectively "REHAVISTA") Germany's largest provider of augmentative and alternative communication (AAC) products and services, employing over 170 staff. The company, which has six offices across Germany, provides a range of AAC and assistive technology products and has a strong reputation for excellent service. LogBUK is a subsidiary company to REHAVISTA, providing independent speech and language therapy to help AAC users achieve the best outcomes through specialist clinical support.

 

The transaction was funded by the Group's debt facility with CareTech subscribing for additional shares in Smartbox such that post-completion, CareTech will own 83% of Smartbox, with the remaining minority ownership continuing to be held by the Smartbox management team.

 

REHAVISTA's reach and expertise is unparalleled in Germany, estimated to be the second largest funded AAC market globally after the USA. With its deep knowledge of assistive technology and established routes to market, this acquisition provides a significant opportunity for Smartbox to expand the products and services available in Germany, expanding on the existing partnership between Smartbox and REHAVISTA, and across Smartbox's global customer base, which spans more than 30 languages and 45 distributors.

    

 

 

The provisional acquisition table is as follows:

Book values

£000s

Fair value

adjustments

£000s

Total

£000s

Intangible assets

24

839

863

Goodwill

31

(31)

-

Property plant & equipment

471

-

471

Right-of-use asset

900

-

900

Trade and other receivables

1,488

(131)

1,357

Inventory

1,466

-

1,466

Cash

175

-

175

Corporation tax

(61)

-

(61)

Deferred tax

-

(268)

(268)

Trade and other payables

(1,846)

-

(1,846)

Lease liability

(900)

-

(900)

Loans and other borrowings

(578)

-

(578)

Net assets on acquisition

1,170

409

1,579

 

 

 

 

Consideration paid

8,573

Goodwill

6,994

Consideration paid was:

£000

Cash

8,295

Deferred consideration

278

Total consideration

8,573

Reconciliation to the cash flow statement

£000

Cash paid

8,295

Cash acquired

(175)

Payments for business combination net of cash acquired

8,120

Goodwill arises as a result the surplus of consideration over the fair value of the separately identifiable assets acquired.

Costs relating to this acquisition are expensed in the Income Statement in accordance with IFRS3 and are identified in note 3 non underlying items.

Goodwill is attributable to the future economic benefits arising from assets which are not capable of being individually identified and separately recognised, these include value of the assembled workforce within the business acquired. Other intangible assets acquired relate to the REHAVISTA trade name.

Dmetco-Bayti

 

On 4 February 2022, the Group completed two further acquisitions in the United Arab Emirates (UAE), Wellness Center ('Wellness') and Dmetco-Bayti Group ('Dmetco).

 

Dmetco-Bayti is a well-established home healthcare provider managing the daily health and social care needs of its patients across the UAE through two home-grown brands, namely Dmetco Home Healthcare and Bayti Home Healthcare. Established in 2012, it provides home healthcare and physiotherapy services in the emirate of Abu Dhabi, primarily to UAE nationals, through a team of over 150 registered healthcare professionals. Dmetco-Bayti also caters to patients who require physiotherapy and rehabilitation services. The estimated patient size for in-home health and social care services in the UAE is 10,000, with Dmetco-Bayti currently managing 120 individuals.

 

AS Group has acquired a 70% interest in Dmetco-Bayti paying upfront consideration of £7.3m in cash with a further £3.1m in cash deferred and £0.6m in cash payable through an earn-out mechanism. The transaction has been funded by the Group's existing cash resources and debt facility.

 

 

The provisional acquisition table for Dmetco-Bayti is as follows:

Book values

£000s

Fair value

adjustments

£000s

Total

£000s

Intangible assets

-

7,166

7,166

Property plant & equipment

84

-

84

Trade and other receivables

1,226

(52)

1,174

Cash

1,150

-

1,150

Trade and other payables

(1,407)

-

(1,407)

Net assets on acquisition

1,053

7,114

8,167

Less: Non-controlling interest

 

 

(2,450)

 

 

 

5,717

Consideration paid

10,982

Goodwill

5,265

Consideration paid

Cash

7,257

Contingent consideration

3,725

Total consideration

10,982

Cash paid

7,257

Cash acquired

(1,150)

Cash contribution by existing owners

(3,540)

Payments for business combination net of cash acquired

2,567

 

Goodwill arises as a result the surplus of consideration over the fair value of the separately identifiable assets acquired.

Costs relating to this acquisition are expensed in the Income Statement in accordance with IFRS3 and are identified in note 3 non underlying items.

Goodwill is attributable to the future economic benefits arising from assets which are not capable of being individually identified and separately recognised, these include value of the assembled workforce within the business acquired. Other intangible assets acquired comprise customer relationships and the Dmetco-Bayti trade name.

Wellness Center

 

Established in 2015 by Shafqat Malik, co-founder and CEO of AS Group, the Abu Dhabi-based Wellness provides integrated physical health consultations and surgical services serving c.7000 patients per month. Wellness's operations are an integral part of the founders' vision to provide a continuum of care for AS Group's mental healthcare patients through quality day care, GP and other specialist services. Over 72% of the Groups' revenues are backed by health insurance schemes.

 

CareTech has acquired a 51% interest in the Wellness Group and has paid an upfront consideration of £8.1m in cash with a further £3.9m in cash deferred. The transaction has been funded by the Group's existing cash resources and debt facility.

 

The provisional acquisition table for Wellness is as follows:

Book values

£000s

Fair value

adjustments

£000s

Total

£000s

Intangible assets

-

10,185

10,185

Property plant & equipment

1,025

-

1,025

Right-of-use asset

150

-

150

Trade and other receivables

2,104

(73)

2,031

Inventories

152

-

152

Cash

884

-

884

Trade and other payables

(2,227)

-

(2,227)

Lease liability

(241)

-

(241)

Net assets on acquisition

1,847

10,112

11,959

Less: Non-controlling interest

 

 

(5,803)

 

 

 

6,156

Consideration paid

11,921

Goodwill

5,765

Consideration paid

Cash

8,022

Contingent consideration

3,899

Total consideration

11,921

Cash paid

8,022

Cash acquired

(884)

Payments for business combination net of cash acquired

7,138

 

 

Goodwill arises as a result the surplus of consideration over the fair value of the separately identifiable assets acquired.

Costs relating to this acquisition are expensed in the Income Statement in accordance with IFRS3 and are identified in note 3 non underlying items.

Goodwill is attributable to the future economic benefits arising from assets which are not capable of being individually identified and separately recognised, these include value of the assembled workforce within the business acquired. Other intangible assets acquired comprise customer relationships and the Wellness trade name.

 

 

Appendix: Alternative Performance Measures

 

The Group reports certain non-IFRS performance measures, known as Alternative Performance Measures ('APMs'). The Directors believe that they provide useful supplemental information for the readers of the Annual Report and, when read in conjunction with the IFRS financial information, assist in providing a balanced view of the Group's financial performance and financial position.

 

In assessing its performance, the Group has adopted a number of APMs as the Directors are of the view that these will assist the readers of the accounts when understanding our performance relative to other companies in our sector and in the wider economy. These measures are not defined by IFRS and therefore may not be directly comparable with other companies' adjusted measures. They are not intended to be a substitute for, or superior to, IFRS measurements of profit or earnings per share.

 

We set out below those APMs which management use in assessing its own performance and a reconciliation of those APMs to the statutory IFRS financial statements.

 

a) Underlying EBITDA

 

Underlying EBITDA is defined as Earnings Before Interest, Tax, Depreciation, Amortisation, ExSOP share-based payments charge and non-underlying items (see note (b) below). There is no further intent to issue awards under the ExSOP scheme, these have historically been ad hoc awards and as such not considered a component of underlying EBITDA. Underlying EBITDA is considered the most relevant performance measure in our (and many other) sectors. We reconcile underlying EBITDA to the statutory measure of operating profit on the face of the

income statement in note as below:

 

Six months ended

Six months ended

Year

ended

31 March 2022

31 March 2021

30 September 2021

unaudited

unaudited

audited

£000

£000

£000

Underlying EBITDA

49,086

49,359

100,485

Adjusted for:

 

COVID-19 income

1,559

1,181

2,692

Depreciation

(9,708)

(9,422)

(19,519)

Amortisation of intangible assets

(5,574)

(5,184)

(10,273)

Acquisition expenses

(1,042)

(423)

(759)

Sleep-in provision

-

11,777

11,777

Gain on bargain purchases

-

5,758

5,758

Other non-underlying items

(2,611)

(2,156)

(5,964)

COVID-19 expenses

(5,116)

(1,977)

(4,220)

Share-based payments' charge

(237)

(237)

(473)

Operating profit

 

26,357

48,676

79,504

 

 

 

 

 

 

b) Non-underlying items

Statutory measures are adjusted to exclude those events or transactions that, in the opinion of the Directors, by virtue of unusual size or nature, or an infrequent/one off occurrence, distort the understanding of the performance for the year or comparability between periods. Such items are separately classified as non-underlying items in these accounts. The Directors are of the view that the underlying items will improve a reader's understanding of the core performance of the businesses of the Group.

At the operating cost level, non-underlying items include expenses relating to the acquisition of new businesses; the integration of acquisitions and the reorganisation of the internal operating and management structure and redundancy costs; non-cash charges of amortisation of intangible fixed assets together with any impairment of intangible assets or goodwill; and any other items that may fit this definition. For the year ended 30 September 2021, a reversal of sleep-in provision and a gain on bargain purchase were included in the determination of operating profit. COVID-19 income and costs have been included as non-underlying operating profit for the years ended 30 September 2021 and 30 September 2020. Please refer Note 6 for a detailed explanation as to why each of these items are considered non-underlying.

At the financial expenses level, non-underlying items include costs relating to derivative financial instruments and include the movements during the year in the fair value of the Group's interest rate hedging arrangements which do not qualify for hedge accounting, together with the quarterly cash settlement and accrual thereof. These items are considered by the Directors to meet the definition of non-underlying items.

The impact of current and deferred tax on each of these items are considered in the non-underlying section, in addition to the impact of deferred tax on account of the rate change.

We present a reconciliation of our underlying earnings to our statutory profit on a line by line basis including Operating profit, Finance expenses, Profit before Tax and Taxation as follows:

 

 

 

Six months ended

Six months ended

Year ended

 

 

31 March 2022

31 March 2021

30 September 2021

 

 

unaudited

unaudited

audited

 

Underlying

Non-underlying

Statutory

Underlying

Non-underlying

Statutory

Underlying

Non-underlying

Statutory

£000

£000

£000

£000

£000

£000

£000

£000

£000

Operating profit

39,141

(12,784)

26,357

39,700

8,976

48,676

80,493

(989)

79,504

Financial expenses

(6,905)

(225)

(7,130)

(6,097)

(232)

(6,329)

(12,158)

(1,112)

(13,270)

Profit before tax

32,236

(13,009)

19,227

33,603

8,744

42,347

68,335

(2,101)

66,234

Taxation

(4,530)

796

(3,734)

(7,029)

3,488

(3,541)

(11,889)

(19,017)

(30,906)

Profit for the year

27,706

(12,213)

15,493

26,574

12,232

38,806

56,446

(21,118)

35,328

 

c) Net debt

A key performance indicator for many readers of accounts is the level of net debt within the business. Net debt comprises cash net of all loans and borrowings as defined by the Group's banking facilities. Accordingly, the Group provides information on its net debt which is reconciled to the statutory financial statements as follows:

Six months ended

Six months ended

Year

ended

31 March 2022

31 March 2021

30 September 2021

unaudited

unaudited

audited

£000

£000

£000

Net debt in the balance sheet comprises:

 

Cash and cash equivalents

47,226

61,290

65,560

Loans and borrowings

(319,234)

(317,762)

(317,896)

Shareholder loan

(1,802)

(1,719)

(1,758)

Lease liabilities (i)

(4,497)

(4,909)

(4,567)

Net debt at the end of the period

(278,307)

(263,100)

(258,661)

 

 

 

 

(i) Net debt includes vehicle finance leases included in lease liabilities.

 

d) Underlying earnings per share

Underlying earnings per share is calculated based on underlying profit for the year as calculated in note (b) above.

 

 

 

 

 

 

e) Operating cash flows before non-underlying items

Operating cash flows before non-underlying items is calculated based on operating cash flows adjusted non-underlying cash flows as reconciled below.

 

Six months ended

Six months ended

Year

ended

31 March 2022

31 March 2021

30 September 2021

unaudited

unaudited

audited

£000

£000

£000

Operating cash flows before non-underlying items

49,910

49,215

96,594

Non-cash adjustment

723

-

903

Integration and restructuring costs

(1,952)

(971)

(4,177)

Payment of charitable donations

(659)

(601)

(1,203)

COVID-19 receipts

1,559

1,181

2,692

COVID-19 payments

(5,116)

(1,977)

(4,220)

Payment of acquisition costs

(1,042)

(423)

(759)

Cash inflows from operating activities

43,423

46,424

89,830

 

 

 

 

 

 

 

Directors and Advisers

 

Company Number Solicitors

04457287 Charles Russell Speechlys

5 Fleet Place

Registered Office London EC4M 7RD

5th Floor, Metropolitan House

3 Darkes Lane

Potters Bar

Herts EN6 1AG 

Directors

Farouq Sheikh (Group Executive Chairman) Registrars

Haroon Sheikh (Group Chief Executive Officer) Link Asset Services

Christopher Dickinson (Group Chief Financial Officer) Northern House

Michael Adams (Care Partnerships Director) Woodsome Park

Adrian Stone (Independent Non-Executive Director) Fenay Bridge

James Cumming (Independent Non-Executive Director) Huddersfield

Moira Livingston (Independent Non-Executive Director) West Yorkshire HD8 0GA

Company Secretary Auditor

Christopher Dickinson Grant Thornton UK LLP

30 Finsbury Square

Nominated Adviser and Joint Broker London

Panmure Gordon (UK) Limited EC2A 1AG

One New Change

London EC4M 9AF

 

Joint Brokers

Numis

14 Gresham Street

London

EC2V 7BF

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR SFFESIEESEDM
Date   Source Headline
28th Sep 20227:00 amRNSCancellation - CareTech Holdings PLC
27th Sep 20223:25 pmBUSForm 8.3 - CareTech Holdings plc
27th Sep 20223:00 pmRNSForm 8.3 - Caretech Holdings PLC
27th Sep 20221:55 pmRNSForm 8.3 - CARETECH HOLDINGS PLC
27th Sep 202210:32 amRNSCARETECH SCHEME OF ARRANGEMENT BECOMES EFFECTIVE
27th Sep 20229:46 amRNSForm 8.5 (EPT/RI) - CareTech Holdings Plc
27th Sep 20229:31 amRNSForm 8.5 (EPT/RI) - CareTech Holdings plc
27th Sep 20227:30 amRNSSuspension – CareTech Holdings PLC
26th Sep 20224:12 pmRNSUpdate on Financing Arrangements
26th Sep 20223:25 pmBUSForm 8.3 - CareTech Holdings plc
26th Sep 20223:05 pmBUSForm 8.3 - CareTech Holdings plc
26th Sep 202210:58 amRNSForm 8.5 (EPT/RI) - CareTech Holdings plc
26th Sep 20229:44 amRNSForm 8.3 - Caretech Holdings Plc
26th Sep 20228:57 amRNSForm 8.5 (EPT/RI) - CareTech Holdings Plc
23rd Sep 20224:29 pmRNSCourt Sanction of Scheme of Arrangement
23rd Sep 20223:25 pmBUSForm 8.3 - CareTech Holdings plc
23rd Sep 20222:39 pmRNSForm 8.3 - CARETECH HOLDINGS PLC
23rd Sep 202212:59 pmRNSForm 8.3 - CARETECH HOLDINGS PLC
23rd Sep 20229:55 amRNSForm 8.5 (EPT/RI) - CareTech Holdings Plc
23rd Sep 20229:29 amRNSForm 8.3 - Caretech Holdings Plc
23rd Sep 20228:53 amRNSForm 8.5 (EPT/RI) - CareTech Holdings plc
22nd Sep 20226:29 pmRNSForm 8.3 - CARETECH HOLDINGS PLC
22nd Sep 20225:30 pmRNSCareTech Holdings
22nd Sep 20223:25 pmBUSForm 8.3 - CareTech Holdings plc
22nd Sep 20223:00 pmRNSForm 8.3 - Caretech Holdings PLC
22nd Sep 202210:23 amGNWMan Group PLC : Form 8.3 - Caretech Holdings PLC
22nd Sep 20229:26 amRNSForm 8.5 (EPT/RI) - CareTech Holdings Plc
21st Sep 20223:25 pmBUSForm 8.3 - CareTech Holdings plc
21st Sep 20221:42 pmRNSForm 8.3 - CARETECH HOLDINGS PLC
21st Sep 20227:16 amRNSForm 8.3 - CARETECH HOLDINGS PLC AMENDMENT
20th Sep 202211:29 amGNWForm 8.3 - [CareTech Holdings plc - 16 09 2022] - (CGWL)
20th Sep 20229:48 amRNSForm 8.3 - Caretech Holdings Plc
20th Sep 20229:09 amRNSForm 8.5 (EPT/RI) - CareTech Holdings Plc
20th Sep 20227:00 amBUSForm 8.3 - CareTech Holdings plc
19th Sep 20223:00 pmRNSForm 8.3 - Caretech Holdings PLC
19th Sep 20221:08 pmRNSForm 8.3 - CARETECH HOLDINGS
16th Sep 20223:25 pmRNSForm 8.3 - CareTech Holdings PLC
16th Sep 20223:25 pmBUSForm 8.3 - CareTech Holdings plc
16th Sep 20222:24 pmRNSForm 8.3 - Caretech Holdings
16th Sep 20221:48 pmRNSForm 8.3 - CARETECH HOLDINGS PLC
16th Sep 202212:09 pmGNWForm 8.3 - [CareTech Holdings plc 15 09 2022] - (CGWL)
16th Sep 20229:30 amRNSForm 8.5 (EPT/RI) - CareTech Holdings Plc
16th Sep 20229:29 amRNSForm 8.3 - Caretech Holdings Plc
15th Sep 20223:25 pmBUSForm 8.3 - CareTech Holdings plc
15th Sep 20222:09 pmRNSForm 8.3 - CARETECH HOLDINGS PLC
15th Sep 202211:44 amRNSForm 8.3 - Caretech Holdings PLC
15th Sep 20229:30 amRNSForm 8.5 (EPT/RI) - CareTech Holdings plc
14th Sep 20225:26 pmRNSHolding(s) in Company
14th Sep 20223:25 pmBUSForm 8.3 - CareTech Holdings plc
14th Sep 20223:00 pmRNSForm 8.3 - Caretech Holdings PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.